POINT Biopharma Global Inc.·4

Apr 5, 10:48 AM ET

JENSEN JESSICA D. 4

4 · POINT Biopharma Global Inc. · Filed Apr 5, 2022

Insider Transaction Report

Form 4
Period: 2022-04-01
JENSEN JESSICA D.
EVP Clinical Development
Transactions
  • Award

    Stock Option (Right to Buy)

    2022-04-01+13,76613,766 total
    Exercise: $7.91Exp: 2028-04-01Common Stock (13,766 underlying)
Footnotes (1)
  • [F1]The option vests 25% on the first anniversary of the date of grant with the remaining 75% vesting in three equal annual installments thereafter.

Documents

1 file
  • 4
    tm2211495-1_4seq1.xmlPrimary

    OWNERSHIP DOCUMENT